Evidence map›Paper›PMID 31388753›Full record

ArticleLung2019

The Frequency of Monocyte Chemoattractant Protein-1 Gene Polymorphism in Obstructive Sleep Apnea Syndrome.

Buğra Kerget, Omer Araz, Haktan Bağış Erdem, Metin Akgün

Abstract read
PubMed Publisher
In one paragraph

Article in Lung, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Buğra KergetDepartment of Pulmonary Diseases, Health Sciences University Erzurum, Regional Education and Research Hospital, Erzurum, Turkey. bjkerget1903@gmail.com.ORCID 0000-0002-6048-1462
Omer ArazDepartment of Pulmonary Diseases, Ataturk University School of Medicine, 25240, Erzurum, Turkey.
Haktan Bağış ErdemMedical Genetics Unit, Health Sciences University, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
Metin AkgünDepartment of Pulmonary Diseases, Ataturk University School of Medicine, 25240, Erzurum, Turkey.
Atatürk University · TRErzurum Regional Training and Research Hospital · TRSağlık Bilimleri Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn obstructive sleep apnea syndrome (OSAS) many proinflammatory cytokines are released from activated endothelial cells due to repeated decreases in arterial oxygen saturation. Some of these proinflammatory cytokines are involved in the etiology of coronary artery disease (CAD). Although the association between OSAS and CAD is known, risk factors for CAD have not been determined in this patient group. Monocyte chemoattractant protein-1 (MCP-1) is a proinflammatory cytokine that plays a key role in the development of atherosclerosis. In this study, we compared the frequency of MCP1 rs1024610-rs1024611 single-nucleotide polymorphisms (SNPs) in OSAS patients with no comorbidity, OSAS patients with no comorbidity except CAD, and healthy individuals. MATERIAL AND

methodsThe study included 301 subjects. Two hundred one patients with OSAS (OSAS only and OSAS + CAD groups) and 100 healthy control subjects underwent polysomnography. MCP1 rs1024610 and rs1024611 mutation frequencies were determined.

resultsBody mass index, apnea-hypopnea index, triglyceride levels, and mean oxygen desaturation were significantly higher in the OSAS patients than in the healthy population (p < 0.05). In MCP1 rs1024611 SNP analysis, homozygous mutation was significantly more common in the OSAS + CAD group than in the OSAS and control groups (p < 0.001). MCP1 rs1024610 SNP analysis showed no significant differences among the study groups.

conclusionOSAS patients with homozygous MCP1 rs1024611 SNP are at higher risk for CAD. The MCP1 rs1024610 SNP was not associated with incidence of CAD. Patients with OSAS and MCP1 rs1024611 homozygous mutation are more susceptible to CAD and early detection and treatment may significantly reduce mortality and morbidity.

Indexed as

MutationPolymorphism, Single NucleotideAdultAgedCase-Control StudiesChemokine CCL2Coronary Artery DiseaseFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHeterozygoteHomozygoteHumansMaleMiddle AgedMutation RateCCL2 protein, humanChemokine CCL2AtherosclerosisCoronary arterial diseasesMonocyte chemoattractant protein-1Obstructive sleep apnea syndrome

Identifiers

PMID31388753
OpenAlexW2966815490

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.